Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-03-27
1993-09-07
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514255, 536 64, A61K 3702, C07K 900
Patent
active
052429016
ABSTRACT:
Disclosed is a method for preventing cardiotoxicity in a human in need of such preventive treatment, the method including administering an effective amount of a bisdioxopiperazine. Also disclosed is a method for preventing cardiotoxicity induced by the administration of an anthracycline. Further, a tumoricidal, cardioprotective combination of agents is disclosed.
REFERENCES:
patent: 4477444 (1984-10-01), Suarato et al.
patent: 4755619 (1988-07-01), Creighton et al.
patent: 4824944 (1989-04-01), Stefanska et al.
Research Communications in Chemical Pathology & Pharmacology, Herman et al., Reduction of Chronic Daunorubicin Cardiotoxicity by ICRF-187 in Rabbits, vol. 31, No. 1, (Jan. 1981).
"Prevention of Adriamycin-Induced Cardiotoxicity by ICRF-187", R. J. Belt, Abstract C-105, ASCO Abstracts, p. 24, Mar. 1984.
Herman et al., Res. Com. Chem. Path. Pharm. 38:85-97 (1981).
Herman et al., Cancer Res. 41:3436-40 (1981).
Von Hoff et al., Cancer Treat. Rep. 65:249-252 (1981).
Speyer et al., N. Engl. J. Med. 319:745-52 (1988).
Green, Path. Biol. 35:49-53 (Jan. 1987).
Doroshow J. H., Locker G. Y., Myers C. E.: Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J. Clin. Invest. 1980;65:129-135.
Olson R. D., Boerth R. C., Gerber J. G., Nies A. S.: Mechanism of Adriamycin cardiotoxicity: evidence for oxidative stress. Life Sciences 1981;29:1393-1401.
Doroshow J. H.: Effect of anthracycline antibiotics on oxygen radical formulation in rat heart. Cancer Research 1983;43:460-472.
Gutteridge J. M. C.: Lipid peroxidation and possible hydroxy radical formation stimulated by the self-reduction of a doxorubicin-iron(III) complex. Biochem. Pharm. 1984;33(11):1725-1728.
Bristow M. R., Minobe W. A., Billingham M. E., Marmor J. B., Johnson G. A., Ishimoto B. M., Sageman W. S., Daniels J. R.: Anthracycline-associated cardiac and renal damage in rabbits. Lab. Invest. 1981;45(2):157162.
Decorti G., Klugmann R. B., Candussio L., Basa M., Mallardi F., Grill V., Baldini L.: Effect of polyethylene glycol 400 on Adriamycin induced histamine release, Eur. J. Cancer Clin. OncoL 1986;22(7):793-799.
Decorti G., Klugmann F. B., Candussio L., Baldini L.: Characterization of histamine secretion induced by anthracyclines in rat peritoneal mass cells. Biochem. Pharm. 1986;35(12):1939-1942.
Zorzato F., Saiviati G., Facchinetti T., Volpe P.: Doxorubicin induces calcium release from terminal cisternae of skeletal muscle: a study on isolated sarcoplasmic reticulum and chemically skinned fibers. J. Biol. Chem. 1985;260(12):7349-7355.
Caroni P., Villani F., Carafoli E.: The cardiotoxic antibiotic doxorubicin inhibits the Na.sup.+ /Ca.sup.2+ exchange of dog heart sarcolemmal vesicles. Elsevier 1981;130(2):184-188.
Anghileri L. J.: Ca.sup.2+ -Transport inhibition by the antitumor agents Adriamycin and daunomycin. Arzneim.-Forsch./Drug Res. 1977;27(1),6:1177-1180.
Boucek R. J., Olson R. D., Brenner D. E., Ogunbunmi E. M., Inui M., Fleischer S.: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: a correlative study of cardiac muscle with isolated membrane fractions. J. Biol. Chem. 1987;262(33):15851-15856.
Tomlinson C. W., Godin D. V., Rabkin S. W.: Adriamycin cardiomyopathy: implications of cellular changes in a canine model with mild impairment of left ventricular function. Biochem. Pharm. 1985;34(22):4033-4041.
Iwamoto Y., Hansen I. L., Porter T. H., et al.: Inhibition of coenzyme Q.sub.10 -enzymes, succinoxidase and NADH-oxidase, by Adriamycin and other quinones having antitumor activity. Biochem. Biophys. Res. Commun. 1974;58:633-638.
Bertazzoli C., Ghione M.: Adriamycin associated cardiotoxicty: research on prevention with coenzyme Q. Pharm. Res. Comm. 1977;9(3):235-244.
Zbinden G., Bachmann E., Bolliger H.: Study of coenzyme Q in toxicity of Adriamycin. 1977 Elsevier/North-Holland Biomedical Press, p. 219.
Rosenoff S. H. Brooks E., Bostick F., Young R. C.: Alternations in DNA synthesis in cardiac tissue induced by Adriamycin in vivo-Relationship to fatal toxicity. Biochem. Pharm. 1971;24:18981901.
Torti F. M., Bristow M. R., Howes A. E., Aston D., Stockdale F. E., Carter S. K., Kohler M., Brown B. W., Billingham M. E.: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann. Intern. Med. 1983;99(6):745-749.
Legha S. S., Benjamin R. S., Mackay B., et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 1982;96:133-139.
Weiss A. J., Metter G. E., Fletcher W. S., Wilson W. L., Grage T. B., Ramirez G.: Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 1976;60:813-822.
Weiss A. J., Manthel R. W.: Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 1977;40:2046-52.
Byfield J. E., Seagren S., Chan P. Y. M.: Adriamycin (AD) cardiotoxicity (CT): clues to mitigation, ASCO Abstracts 1977;MARCH:275.
Nagineni C. N., Yamada T., Yang J. J., Seraydarian M. W.: Effects of Adriamycin on enzymes of adenine nucleotide metabolism in heart cell cultures. Res. Commun. Chem. Path. Pharm. 1985;50(2):301305.
Pelikan P. C. D., Weisfeldt M. L., Jacobus W. E., Miceli M. V., Bulkley B. H., Gerstenblith G.: Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alternations in the isolated, perfused rat heart. J. Cardiovasc. Pharm. 1986;8:1058-1066.
Gibbs C. L.: Acute energetic effects of daunomycin on rabbit heart muscle. J. Cardiovasc. Pharm. 1985;7:556-561.
Seraydarian M. W., Artaza L.: Modification by adenosine of the effect of Adriamycin on myocardial cells in culture. Cancer Research 1979;39:2940-2944.
Saman S., Jacobs P., Opie L. H.: Mechanism of acute anthracycline cardiotoxicity in isolated rat hearts: Carminomycin versus Daunomycin. Cancer Research 1984;44:1316-1320.
Villani F., Piccinini F., Merelli P., Favalli L.: Influence of Adriamycin of calcium exchangeability in cardiac muscle and its modification by ouabian. Chemical Pharm. 1977;27:985-987.
DiMarco A., Dasdia T., Pastori W.: Interaction of calcium ions and cAMP on the cytotoxic effect of doxorubicin. Tumori 1984;70:217-221.
Singal P. K., Panagia V.: Direct effects of Adriamycin on the rat heart sarcolemma. Res. Commun. Chem. Path. Pharm. 1984;43(1):67-72.
Lazarus M. L., Rossner K. L., Anderson K. M.: Adriamycin-induced alterations of the action potential in rat papillary muscle, Cardiovasc. Res. 1980;14:446-450.
Azuma J., Serelakis N., Hasegawa H., et al.: Adriamycin cardiotoxicity: possible pathogenic mechanisms. J. MoL. Cell. Cardiol. 1981;13:381-397.
Mhatre R., Herman E., Huidobro A., Waravdekav V.: The possible relationship between metabolism and cardiac toxicity of daunomycin and related compounds. J. Pharm. Exp. Ther. 178:216-222.
Wheeler D. M. S.: Another hypothesis concerning the antitumor activity and cardiotoxicity of daunorubicin (NSC-82151) and Adriamycin (NSC-1 23127). Cancer Chemother. Reports, Part 1, 1975;59(2):258259.
Levey G. S., Levey B. A., Ruiz E., Lehotay D. C., Selective inhibition of rat and human cardiac guanylate cyclase in vitro by doxorubicin (Adriamycin): possible link to anthracycline cardiotoxicity. Cardiol. 1979;l 1:591-599.
Lehotay D. C., Levey B. A., Rogerson B. J., Levey G. S.: Inhibition of cardiac guanylate cyclase by doxorubicin and some of its analogs: possible relationship to cardiotoxicity. Cancer Treat. Reports 1982;66(2):311-316.
Law J., Fumagalli A., Schein P. S., Rahman A.: Selective inhibition of cardiac cyclic nucleotide phophodiesterases by doxorubicin and daunorubicin. Life Sciences 1985;36:589-599.
Fiallo M. M. L., Garnier-Suillerot A.: Interaction of Adriamycin with cardiolipin-containing vesicles: evidence of an embedded site for the dihydroanthraquinone moiety. Biochem. et Biophys. Acta 1986;854-143-146.
Siegfried J. A., Kennedy K. A., Sartorelli A. C., Tritton T. R.: The role of membranes in the mechanism of action of the antineoplastic agent Adriamycin: spin-labeling studies
Green Michael D.
Muggia Franco M.
Speyer James L.
Lee Lester L.
New York University
LandOfFree
Reduction of anthracycline induced cardiotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of anthracycline induced cardiotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of anthracycline induced cardiotoxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-487841